Objective-Type 1 diabetes (T1DM) is a proinflammatory state and confers an increased risk for vascular complications.
T ype 1 diabetes (T1DM) is a proinflammatory state, as evidenced by increased levels of C-reactive protein, inflammatory cytokines, and nuclear factor-B (NF-B) activation [1] [2] [3] ; these increases are further accentuated in T1DM patients with microvascular complications. 4 -7 Diabetic nephropathy (DN) is the leading cause for end stage renal disease in the United States, affecting 30% of T1DM patients. [7] [8] [9] The mechanism of kidney injury in diabetes is multifactorial, and recent findings suggest an important role for activation of immunologic pathways. 10 Studies support increased biomarkers of inflammation in diabetic kidneys. [11] [12] [13] The emerging concept is that activation of the innate immune system and inflammation via Toll-like receptor (TLR) activation in the pathogenesis of T1DM and its complications are significant. 14 -18 Recent findings have shown increased TLR2/4 expression, signaling, ligands, and functional activation in T1DM subjects compared with controls, 19, 20 which is further accentuated in monocytes of T1DM with microvascular complications (mainly nephropathy). 16 Overactivation of TLRs contributes to the pathogenesis of acute kidney injury, ischemic renal damage, and allograft rejection. 21 Recently, Brown et al 22 showed in a murine model of crescentic glomerulonephritis that administration of a synthetic TLR2 ligand (Pam3CSK4) significantly influenced disease severity through a TLR2-dependent mechanism. These data imply that selective targeting of TLR2 and the signaling pathways may have major clinical implications. However, at the present time, the role of TLR2 in diabetic vascular complications including DN is not known.
There are distinct changes in kidney structure and clearance function in early stages of diabetes preceding the appearance of pathological levels of albumin in urine. Thus, renal hypertrophy and onset of glomerular accumulation of extracellular matrix proteins in the form of thickening of glomerular basement membrane and mesangial matrix expansion due to an increase in laminin content are seen generally within days of onset of diabetes in rodent models. 23 Thickening of the glomerular basement membrane is associated with transforming growth factor-␤ (TGF-␤), and laminin expression can occur early in DN and may even precede albuminuria. Nephrin, a transmembrane receptor protein essential for maintaining the structure and function of the glomerular slit diaphragm, is significantly decreased in DN. 24, 25 Nephrin in podocytes interacts with other proteins, such as podocin, and regulates a number of cell signaling pathways, including stimulation of mitogen-activated protein kinases. 26 TGF-␤ expression in DN is known to increase extracellular matrix protein synthesis (laminin, fibronectin, etc) and decrease matrix degradation. 27, 28 However, the interaction of the innate immunity pathway involving TLRs and well-established biochemical changes (such as the increase in matrix laminin and TGF-␤ expression, the decrease in podocyte number and slit diaphragm proteins, and albuminuria in early stage of DN) has not been studied. Thus, the aim of this study was to examine whether genetic deficiency of TLR2 attenuates the increased inflammation associated with T1DM and ameliorates early abnormalities in DN.
Methods
Please see details in the supplemental materials, available online at http://atvb.ahajournals.org.
Animals
TLR2Ϫ/Ϫ mice (male, 8 to 10 weeks of age) generated on a C57BL/6J genetic background (wild-type [WT]) were purchased from the Jackson Laboratory (Bar Harbor, ME). Diabetes was induced by injecting multiple low doses of streptozotocin (STZ) (Sigma, 50 mg/kg body weight IP daily for 4 days), a widely accepted method for inducing T1DM in mice, 29 and insulin pellets (2 U/day) were implanted in the mice to maintain compensated hyperglycemia.
Flow Cytometry
Surface TLR2 and TLR4 expression and markers of M1 phenotype (Ly6C, interleukin-6 [IL-6], chemokine CC receptor 2) and M2 phenotype (CD206, CD163) in peritoneal and kidney macrophages was determined by flow cytometry as described previously. 30, 31 Levels of serum amyloid P component were analyzed by ELISA. Macrophage, serum, and kidney tissue levels of IL-1␤, IL-6, KC/ IL-8, inducible protein (IP)-10, monocyte chemoattractant protein-1 (MCP-1), and tumor necrosis factor-␣ (TNF-␣) were measured using a multiplex cytokine assay Intraassay and interassay CV were determined to be Ͻ14%.
Nuclear/Cytoplasmic Extracts and NF-B Transcription Factor Assays
Nuclear and cytoplasmic extracts were prepared from isolated macrophages and kidneys as described previously. 32
Western Blotting
Western blot analysis was used to examine the downstream signaling events.
Small Interfering RNA Transfection Assays
THP-1 cells (American Type Culture Collection) were incubated in normoglycemic (low glucose: 5.5 mmol/L) and hyperglycemic (high glucose: 15 mmol/L glucose) conditions for 48 hours with specific TLR2 or scrambled small interfering RNA (siRNA) (Ambion) as described previously. 32
Transmission Electron Microscopy of Diabetic Kidneys and Immunohistochemistry
Structural changes in diabetic kidneys were detected using transmission electron microscopy and following the College of American Pathology protocols of the University of California Davis Medical School as described previously. 33, 34 
Statistical Analysis
Statistical analyses were performed using SAS. Data are expressed as meanϮSD for parametric data and as median and interquartile range for nonparametric data. Following ANOVA, parametric data were analyzed using paired 2-tailed t tests, and nonparametric data were analyzed using Wilcoxon signed rank tests. The level of significance was set at PϽ0.05. The Pearson and Spearman correlations were computed for variables of interest such as nephrin, podocin, laminin, WT-1 score, podocyte width, and microalbuminuria.
Results
Baseline characteristics of the mice are provided in the Table. There were no significant differences in body weight or lipid levels between the 4 groups of mice. Following STZ injection, as expected, there was significant elevation in glucose levels compared with WT or TLR2Ϫ/Ϫ mice (Table) .
TLR2 and TLR4 expression was examined in all the groups. Compared with nondiabetic WT mice, WT diabetic mice (WTϩSTZ) had increased expression of both TLR2 and TLR4 in macrophages, whereas TLR2Ϫ/Ϫdiabetic mice (TLR2Ϫ/Ϫϩ STZ) had increased expression only of TLR4 ( Figure 1a ). The extremely low mean fluorscence intensity for TLR2 in TLR2Ϫ/Ϫ mice was consistent with the isotype controls (background). TLR2 levels were significantly increased in kidney macrophages of WTϩSTZ mice compared with WT mice (WT: 46Ϯ11 mean fluorscence intensity/10 5 cells; WTϩSTZ: 75Ϯ21 mean fluorscence intensity/10 5 cells; PϽ0.05). TLR2 activates NF-B via MyD88, resulting in transcription of proinflammatory genes. 18 Infiltrating macrophage-derived products in the diabetic kidney induce inflammation and are involved in the subsequent development and progression of DN. 11, 12, 35 However, it is not clear whether macrophage TLR2-mediated inflammation plays a role in this process. Therefore, levels of MyD88, interleukin-1 receptor associated kinase (IRAK-1) protein phosphorylation, Trif, interferon regulatory factor 3, and NF-B activity were examined in peritoneal macrophages of the mice. TLR2Ϫ/Ϫ ϩSTZ mice showed significant reduction in MyD88 expression and phosphorylation of IRAK-1, whereas there was no significant abrogation of non-MyD88 dependent signaling proteins, such as Trif and interferon regulatory factor 3 ( Figure 1b ), compared with the WTϩSTZ mice. As shown in Figure 1c , concomitant with the activation of MyD88dependent signaling cascade, WTϩSTZ mouse macrophages had significantly increased nuclear NF-B activity compared with WT and TLR2Ϫ/Ϫ mice. Furthermore, compared with WTϩSTZ mice, there was a significant decrease in STZinduced NF-B activity in the TLR2Ϫ/ϪϩSTZ mice (55% reduction, PϽ0.001). In addition, there was significant increase in MyD88 (50%) and phosphorylation of IRAK-1 (63%) activity in WTϩSTZ mice compared with WT mice (Figure 1b ).
NF-B activation leads to increased inflammatory gene expression. To study the functional significance of reduced NF-B activation in diabetic TLR2Ϫ/Ϫ mice, we measured levels of proinflammatory chemokines and cytokines known to be activated by TLR induction. Figure 2 depicts serum levels of cytokines/chemokines. WTϩSTZ mice exhibited significantly increased levels of IL-1␤, IL-6, KC/IL-8, IP-10, MCP-1, and TNF-␣ compared with nondiabetic WT mice (PϽ0.001), and all were significantly attenuated in TLR2Ϫ/ϪϩSTZ mice (PϽ0.001). TNF levels, though decreased in TLRϪ/ϪϩSTZ mice compared with WTϩSTZ mice, did not reach statistical significance (Pϭ0.071). We also examined IL-10 levels, which were not significantly altered in TLR2Ϫ/ϪϩSTZ compared with WTϩSTZ mice. In addition, serum amyloid P component levels were significantly increased in WTϩSTZ mice compared with nondiabetic WT mice, and this increase was significantly attenuated Figure 1 . a, Surface expression of TLR2 and TLR4. Peritoneal macrophages were obtained from WT (nϭ5), TLR2Ϫ/Ϫ (nϭ5), WTϩSTZ (nϭ20), and TLR2Ϫ/ϪϩSTZ (nϭ22) mice at 6 weeks, and surface expression of TLR2 and TLR4 was assessed by flow cytometry as described in Methods. Values are expressed as mean fluorscence intensity (MFI)/10,000 cells (meanϮSD). *PϽ0.001 vs WT and TLR2Ϫ/Ϫ; †PϽ0.001 vs WT or WTϩSTZ; ‡PϽ0.05 vs WT. b, TLR2-MyD88 dependent signaling: MyD88, interleukin-1 receptor associated kinase (IRAK-1) phosphorylation, interferon regulatory factor 3 (IRF3), Trif, and nuclear p65 protein levels were measured in peritoneal macrophage lysates from WTϩSTZ (nϭ20) and TLR2Ϫ/ϪϩSTZ mice (nϭ22) at 6 weeks using Western lot assay. Representative blots and densitometric ratios are depicted in the figure. Values are expressed as protein/␤-actin ratio (meanϮSD). *PϽ0.001 vs WTϩSTZ mice. Total IRAK-1 and ␤-actin were used as internal controls. c, Nuclear NF-B activation in peritoneal macrophages of WT (nϭ5), TLR2Ϫ/Ϫ (nϭ5), WTϩSTZ (nϭ20), and TLR2Ϫ/ϪϩSTZ (nϭ22) mice at 6 weeks was determined by Trans-AM activity assay and normalized to nuclear protein as described in Methods. Values are expressed as ng/mg of protein (meanϮSD). *PϽ0.005 vs WT and TLR2Ϫ/Ϫ; †PϽ0.001 vs WTϩSTZ mice.
in the diabetic TLR2Ϫ/Ϫ mice (median serum amyloid P component in WTϩSTZ: 77 g/mL; in TLR2Ϫ/Ϫϩ STZ mice: 28 g/mL; PϽ0.001). Similar results were obtained for cytokine/chemokine release from peritoneal macrophages (Supplemental Figure I ). TLR2Ϫ/ϪϩSTZ mouse macrophages released significantly lesser amounts of IL-1␤ (48% reduction, PϽ0.01), IL-6 (44% reduction), KC/IL-8 (64% reduction, PϽ0.001), IP-10 (66% reduction, PϽ0.001), and MCP-1 (66% reduction, PϽ0.001) compared with WTϩSTZ mice. The decrease in TNF levels was not significant. Because all the TLRs except TLR3 activate the MyD88 pathway, 18 we used TLR2 siRNA inhibition strategy in human THP-1 cells to confirm the dominant role of TLR2 knockout in decreasing MyD88 in the diabetic milieu. As reported previously, 32 compared with normoglycemic conditions (5.5 mmol/L glucose), there were significant increase in MyD88 and its downstream signaling with high glucose (Supplemental Figure II) . This was attenuated by siRNA to TLR2. Having shown that TLR2 knockout ameliorates the proinflammatory state of diabetes, we next focused on a microvascular complication, DN.
One of the cardinal manifestations of renal involvement in early stages of DN is renal hypertrophy, defined as an increase in the ratio of kidney to body weight. As expected, the kidney to body weight ratios were significantly higher in WTϩSTZ mice compared with WT and lower in TLR2Ϫ/ ϪϩSTZ mice compared with WTϩSTZ mice at both 6 weeks (Table) and 14 weeks (WTϩSTZ: 112.45Ϯ12; TLR2Ϫ/Ϫϩ STZ: 98Ϯ7; PϽ0.05). In addition, we examined protein:DNA ratios to confirm cell hypertrophy, ratios of which were significantly higher in WTϩSTZ mice compared with WT and lower in TLR2Ϫ/ϪϩSTZ mice compared with WTϩSTZ mice (WTϩSTZ: 102Ϯ39; TLR2Ϫ/Ϫϩ STZ: 53Ϯ23; PϽ0.05). The 24-hour urinary microalbumin:creatinine ratios were significantly increased in WT-STZ mice compared with WT mice (median: 86 g/mg creatinine versus 6 g/mg creatinine; PϽ0.001); furthermore, the ratios were significantly decreased in the TLR2Ϫ/Ϫϩ STZ mice (median: 26 g/mg) compared with WTϩSTZ mice (median: 86 g/mg; Pϭ0.015). Thus, we established early DN by the accepted criterion of the animal models of diabetic complications consortium of a 10-fold increase in albuminuria in WT-STZ mice, which is attenuated in TLR2Ϫ/ϪϩSTZ mice. 36 Because we recorded significantly higher levels of proinflammatory cytokines/chemokines and no absolute increase in number of kidney macrophages, we examined the phenotype of macrophages in peritoneum and kidney. As shown in Figure 3a , there was a significant increase in M1 phenotype of both kidney and peritoneal macrophages in WTϩSTZ mice, and this was attenuated in the TLR2Ϫ/ϪϩSTZ mice. Because there was decreased albuminuria in TLR2Ϫ/ϪϩSTZ mice compared with WTϩSTZ mice, we proceeded to examine podocyte morphology. Electron micrographs of the WTϩSTZ and TLR2Ϫ/ϪϩSTZ kidneys were examined using standard electron microscopy techniques. The diabetic group (WTϩSTZ mice) showed foot process effacement and widening of the podocyte villi at 14 weeks after induction of Macrophages were assessed by flow cytometry as described in Methods. M1 phenotype was characterized by positivity for Ly6C, chemokine CC receptor 2 (CCR2), and IL-6, and M2 phenotype was characterized by CD206 and CD 163. *PϽ0.001 vs WT and TLR2Ϫ/Ϫ; †PϽ0.001 vs WT or WTϩSTZ. b, Podocytes in glomeruli of diabetic WT and TLR2Ϫ/Ϫ mice kidneys at 14 weeks were examined by WT-1 immunochemical staining as described in Methods (nϭ11/group). Two representative photographs of WT-1 staining (brown spots in glomeruli) are shown for the 2 groups.
diabetes. This finding was more pronounced at the tips of the capillary loops. These changes were also observed in the TLR2Ϫ/ϪϩSTZ mice kidneys, but to a lesser degree (Supplemental Figure III) . The number of cells positive for WT-1 in 5 high power field was counted, and a WT-1 score was computed. There was significant reduction in WT-1 score in the WTϩSTZ mice, confirming podocyte loss compared with the WT and TLR2Ϫ/Ϫ nondiabetic mice, and this was restored in the TLR2Ϫ/ϪϩSTZ mice (WT-1 score in non-DM mice: 14Ϯ4 cells; WT-STZ mice: 7Ϯ4 cells; TLR2Ϫ/ϪϩSTZ mice: 13Ϯ5* cells per 5 hpf; *PϽ0.05 compared with WT-STZ mice); representative glomeruli are shown in Figure 3b . There was no change in glomerular volume between the groups. Thus, our electron microscopy and WT-1 staining fulfill a second criterion of the animal models of diabetic complications consortium, ie, podocyte loss. When we examined immunochemical staining for mesangial proliferation or macrophage recruitment (using Mac-2 antibody), it was not significantly different between the WTϩSTZ and TLR2Ϫ/ϪϩSTZ mice.
To characterize molecular and signaling changes in kidneys as evidence for early kidney damage under diabetic conditions, nephrin, podocin, laminin, and TGF-␤ expression were measured in all the 4 groups of mice using immunoblot assays after 6 and 14 weeks of persistent diabetes. WTϩSTZ kidneys showed significantly reduced levels of nephrin (250%) and podocin (250%), whereas laminin (185%) and TGF-␤ (180%) expression were higher compared with WT mice at 6 and 14 weeks (Figure 4a and 4b) . Levels of nephrin and podocin were restored in TLR2Ϫ/ϪϩSTZ mice to those of nondiabetic WT mice. TGF-␤ and laminin protein levels were decreased in TLR2Ϫ/ϪϩSTZ kidneys compared with WTϩSTZ kidneys, similar to nondiabetic WT mice. It is important to note that there was a significant correlation between microalbuminuria and podocin (rϭϪ0.56, Pϭ0.03), podocyte width (rϭ0.6, Pϭ0.03), and a trend to significance in the relationship between microalbuminuria and WT-1 score (rϭϪ0.5, Pϭ0.08).
In addition, TLR2, MyD88, and IRAK-1 phosphorylation were increased in WTϩSTZ kidneys and attenuated in TLR2Ϫ/ϪϩSTZ mice (Figure 4a and 4b ). There were no significant differences in the nephrin, podocin, laminin, and MyD88 protein expression in kidneys of nondiabetic WT and TLR2Ϫ/Ϫ mice (Figure 4a and 4b) . Associated with MyD88dependent signaling, WTϩSTZ kidneys had significantly increased nuclear NF-B activity (7Ϯ2 ng/mg protein) compared with those of nondiabetic WT (1.2Ϯ0.2 ng/mg protein) and TLR2Ϫ/Ϫ mice (1Ϯ0.2 ng/mg protein) (PϽ0.002). Furthermore, compared with WTϩSTZ mice, there was a significant decrease in STZ-induced NF-B activity in the kidneys of TLR2Ϫ/ϪϩSTZ mice (2Ϯ0.5 ng/mg protein; 71% reduction; PϽ0.001). Furthermore, we measured inflammation in the kidneys using multiplex assays. IL-1␤, IL-6, KC/IL-8, MCP-1, IP-10, and TNF-␣ concentrations were significantly increased in WTϩSTZ mice compared with nondiabetic WT and TLR2Ϫ/Ϫ mice. There was a significant reduction in the concentration of these inflammatory mediators in TLR2Ϫ/ϪϩSTZ mice compared with WTϩSTZ mice ( Figure 5 ) at 14 weeks.
Discussion
We recently showed that there is increased TLR2 and TLR4 expression and activity in monocytes of T1DM patients compared with matched controls 19 and that these are further accentuated in T1DM patients with microvascular complications, with 66% of the T1DM-microvascular patients having DN. 6, 16 Therefore, in this study, we focused on the contribution of TLR2 to the proinflammatory state of diabetes and a critical microvascular complication, namely, DN, because there is a paucity of data on the role of inflammation in DN. We provide novel evidence supporting these 2 key pathogenic processes using STZ-induced T1DM in WT and TLR2Ϫ/Ϫ mice. First, we showed attenuation of the increased inflammation via circulating cytokine/chemokine levels in the TLR2Ϫ/ϪϩSTZ mice compared with WTϩSTZ mice, despite the expression of other TLRs, including TLR4, being intact; then, using the sentinel inflammatory cell macrophage, we demonstrated inhibition of MyD88-dependent signaling, NF-B activity, and proinflammatory mediators in diabetic TLR2Ϫ/Ϫ mice. Second, we identified early renal changes consistent with DN through increased kidney size, increased albuminuria, decreased nephrin and podocin expression, and increased TGF-␤ and laminin expression in WTϩSTZ mice at 6 and 14 weeks of diabetes. The increased albuminuria at 14 weeks or greater than 10-fold in WTϩSTZ mice compared with WT mice is a validating criterion for DN recommended by animal models of diabetic complications consortium. 36 Also, the increased podocyte foot process widening and effacement and decreased WT-1-positive cells (podocyte loss) is another accepted criterion of the animal models of diabetic complications consortium. 36 Finally, we showed increased MyD88 signaling in WTϩSTZ kidneys coupled with increased IL-6 and MCP-1, which were significantly attenuated in TLR2Ϫ/Ϫ ϩSTZ mice. These molecular changes were restored in TLR2Ϫ/ϪϩSTZ mice, pointing to a critical role for TLR2 in inducing a proinflammatory phenotype in T1DM and attendant nephropathy. We showed increased renal biomarkers of inflammation (IL-1, IL-6, MCP-1) implicated in DN 37,38 that were attenuated in TLR2Ϫ/ϪϩSTZ mice. Using Mac2 antibody in immunohistochemistry, we failed to see increased macrophage recruitment in the kidney. We are unsure whether TLR2 knockout will necessarily reduce macrophage recruitment in the kidney, because it has not been shown previously to persist by 2 groups in the renal ischemia reperfusion model 39, 40 and may be a function of the time course of DN with both TLR2 and TLR4. We clearly showed decreased biomarkers of inflammation implicated in the genesis of DN. In addition, we examined the phenotype of kidney and peritoneal macrophages and showed that there was polarization to the M1 phenotype. These exciting data indicate that macrophages infiltrating the kidney in DN are predominantly of the M1 proinflammatory phenotype and contribute to the increased inflammation seen in DN. Also, periodic acid schiff/silver methaneamine staining did not reveal mesangial proliferation, in spite of the increase in TGF-␤ and laminin.
Rodent models of DN are excellent tools by which to gain insight into the pathogenesis of the disease and to test new therapies. 36, 41, 42 Renal and glomerular hypertrophy are key features of early T1DM and may occur within days of experimental diabetes. 43 In nonobese diabetic mice, renal hypertrophy occurs 10 days after diabetes onset and reaches a plateau by 20 days. 44 However, glomerular sizes did not differ in nonobese diabetic mice from controls in the early stages of diabetes except for partial thickening of basement membrane as revealed by electron microscopy. 43, 44 In agreement with the above studies, we did not see major changes in microalbuminuria at 6 weeks after the onset of T1DM, but there was significantly increased albuminuria at 14 weeks after diabetes onset (Pϭ0.015). These observations are in accordance with the published literature showing that at Ϸ16 weeks, these C57BL6 mice get significant albuminuria and also develop glomerulosclerosis. 45, 46 At the same time, the kidney:body weight and protein:DNA ratios were significantly higher in WTϩSTZ mice compared with WT and lower in TLR2Ϫ/ϪϩSTZ mice compared with WTϩSTZ mice (Table) , indicating early DN. There were significant changes in TGF-␤ consistent with earlier studies using diabetic mice. 47 Thus, enhancing extracellular matrix accumulation or inhibiting extracellular matrix degradation by TGF-␤ makes TGF-␤ a pivotal biomediator in mesangial expansion. 48 Moreover, TGF-␤ has consistently been shown to be increased in renal parenchymal and infiltrating macrophages in the diabetic kidney of humans and experimental models. 49 Our data are consistent with the above studies, and deficiency of TLR2 attenuates TGF-␤ expression in diabetic kidneys. Also, because TGF-␤ promotes mesangial expansion, we quantitated laminin as a readout. Both TGF-␤ and laminin were increased in WTϩSTZ mice compared with nondiabetic and TLR2Ϫ/ϪϩSTZ mice. Had we kept our mice for a longer duration, we anticipate that increased periodic acid schiff positivity would have been evident.
Foot process effacement is a result of retraction, widening, and shortening of the processes of podocytes. Jefferson et al 10 postulated that podocyte effacement could be caused by (1) changes in slit diaphragm-associated proteins, (2) interference with the glomerular basement membrane or podocyteglomerular basement membrane interaction, (3) actin cytoskeleton abnormalities, or (4) alterations in the negative apical membrane domain of podocytes. Because proteinuria is a cardinal clinical characteristic of DN, many studies have focused on the changes in slit diaphragm-associated molecules in DN. Bonnet et al demonstrated a reduction in nephrin mRNA and protein expression in STZ-induced diabetic spontaneously hypertensive rats. 50 In the present study, in conjunction with improvement in proteinuria, diabetic TLR2Ϫ/Ϫ mice showed significant normalization of podocyte villi width and foot process effacement compared with WTϩSTZ mice; concomitantly, there was normalization of the slit membrane proteins nephrin and podocin and normalization of podocytes compared with WTϩSTZ mice. The significant inverse correlation in our study between podocyte protein levels and podocyte number with the accepted clinical biomarker, microalbuminuria, in this diabetic model, suggests that, if confirmed in future studies, they could emerge as novel biomarkers of DN.
Slit diaphragm proteins have become increasingly important in signal transduction and in mediating downstream events in kidney diseases. Recently, nephrin and podocin, 2 slit membrane proteins, have drawn significant attention in the pathogenesis of DN. 51 Menne et al 52 showed that protein kinase C-␣ activation may be an important regulator of nephrin expression and glomerular albumin permeability under diabetic conditions. Dasu et al 32 demonstrated that hyperglycemia-induced TLR2 expression and activation are mediated by protein kinase C-␣ in human monocytes. However, the question of whether TLR2 signaling is involved in mediating the effects of diabetes on the slit-membrane proteins is not known. Both nephrin and podocin serve a survival function for podocytes, 10 and nephrin is a key regulator of podocyte signaling. 53 The decrease in nephrin and podocin in WTϩSTZ kidneys could presage podocyte loss and were partially restored in TLR2Ϫ/ϪϩSTZ mice, indicating the involvement of TLR2 in regulating slit membrane protein expression pivotal in podocyte activity. However, in addition, we show podocyte loss in WT-STZ mice. Also because it has been previously shown that advanced glycation endproductslow-density lipoprotein activates TLR4, 47, 54 this interaction with respect to TLR2 will be studied in the future.
The role of TLR2 has been examined in other disease states. Leemans et al 39 found that TLR2 deficiency resulted in reduced renal dysfunction and tubular damage following ischemia/reperfusion and that this was associated with decreased macrophage numbers in the kidney, but only at day 3, and these differences were lost by day 10. Recent reports have established a protective role of TLR2 deficiency in mice during ischemia/reperfusion injury to maintain coronary endothelial function or left ventricular function. 55, 56 In the present study, our focus was on the proinflammatory state of T1DM and relevance to early DN. Thus, we examined inflammation and key DN biomarkers in macrophages and kidneys using TLR2Ϫ/Ϫ diabetic mice. Furthermore, although various TLRs have been implicated in the pathogenesis of T1DM, 32,55-57 the focus of this study was on the role of TLR2 in the proinflammatory state of T1DM and early molecular changes in DN.
TLRs activate 2 types of downstream signaling pathways: MyD88-dependent and MyD88-independent pathways. 18 TLR2 signals primarily through the MyD88-dependent pathway to induce inflammation. Here, we provide novel evidence, using the STZ-induced diabetes model, that TLR2 knockout results in significant decrease in diabetes-induced inflammation independent of TLR4, because TLR4 levels and TLR4's non-MyD88 dependent signaling proteins (Trif, interferon regulatory factor 3) were unaltered. The decrease in inflammations (ie, release of proinflammatory cytokines and chemokines) was associated with a significant reduction in NF-B activity, MyD88, and phosphorylation of IRAK-1. Similar findings were found when TLR2 was knocked down using siRNA in cells under hyperglycemic conditions. 32 It is worth mentioning that TLR2 deficiency in the diabetic milieu has a profound effect on MyD88-dependent signaling, even with increased TLR4 expression, and warrants further investigation. We have confirmed our in vivo finding using siRNA to TLR2 under hyperglycemic conditions and confirm the decrease in MyD88. Thus, abrogating inflammation in diabetes using TLR2 as a target appears to be a reasonable therapeutic strategy to alleviate inflammation and the associated DN.
In summary, we document 2 novel findings: that genetic deficiency of TLR2 (1) significantly abrogates the proinflammatory state of T1DM up to 14 weeks, despite the other TLRs, including TLR4, being intact; and (2) attenuates incipient DN at the cellular level, as evidenced by normalization of microalbuminuria and retention of podocyte number. In support of our data, Li et al recently documented increased TLR2 expression in both rat and human kidneys with DN. 58 Also, in a previous report, we showed that after a short duration of 2 weeks, there were decreased biomarkers of inflammation in TLR2 knockout STZmice and improvement in wound healing parameters. 59 We are now extending our findings and show the durability of the amelioration of inflammation at 14 weeks in TLR2 knockout-STZ mice, with a benefit on a critical microvascular complication associated with increased morbidity and mortality, DN. Collectively, the published data and the present report support a pivotal role of TLR2 signaling to the proinflammatory state of T1DM and incipient nephropathy. Evidence from prospective trials has emphasized the role of inflammation in contributing to increased complications and cardiovascular events in diabetes. Therapeutic strategies targeted at decreasing TLR2 to abrogate inflammation in diabetes may eventually result in decreased complications, including nephropathy. In this context, we and others have shown that statins, peroxisome proliferator-activated receptor-␥ agonists, 32 and angiotensin receptor blockers 60 decrease both TLR2 and TLR4 expression and signaling.
